Quick Facts: Therapeutic Domain

• Approved Use: Symptomatic management of benign prostatic hyperplasia (BPH) in adult men.
• Primary Benefit: Supports improved urinary flow.
• Scope: Addresses lower urinary tract symptoms associated with BPH.

---

What Alfuzosin STADA Treats: Main Uses and Benefits

Alfuzosin STADA is a prescription medication utilized in adult men for the symptomatic management of benign prostatic hyperplasia (BPH), also referred to as an enlarged prostate. The prostate gland may enlarge as men age, which can contribute to various lower urinary tract symptoms (LUTS).

Treatment with this medication is intended to help ease the functional symptoms associated with BPH. Its therapeutic goal is to support comfortable and improved urinary flow, which can influence an individual's quality of life. The medication is used to manage difficulties such as urinary hesitancy, a weak or intermittent urine stream, and the sensation of incomplete bladder emptying.

Alfuzosin provides assistance with these symptoms, but it does not diminish the overall size of the prostate gland or affect the underlying cause of BPH. Individuals should discuss their treatment plan with a qualified healthcare professional.

Alfuzosin STADA is officially indicated for the management of benign prostatic hyperplasia (BPH) in adult men only. Eligibility is strictly defined by regulatory authorities to exclude certain populations and medical conditions.

Populations Who Cannot Use Alfuzosin STADA (Contraindications)

Category	Official Regulatory Statement
Absolute Contraindications	Hypersensitivity to alfuzosin or any component; moderate or severe hepatic impairment; concurrent use with other alpha1-adrenoceptor antagonists; concurrent use with potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) [Source: FDA Labeling, HPRA SmPC].
Condition-Specific	History of orthostatic hypotension (postural dizziness) is an absolute contraindication [Source: HPRA SmPC].
Age and Gender Status	Women (including during pregnancy or lactation) and the pediatric population (children and adolescents) are not indicated for use [Source: FDA Labeling].

---

Populations Requiring Restricted Use

Use is restricted and requires caution in patients with severe renal impairment ( creatinine clearance < 30 mL/min) or mild hepatic impairment [Source: FDA Labeling]. Caution is also advised for those with pre-existing conditions like coronary artery disease.

Interactions with other medicines and products

The official interaction profile for Alfuzosin STADA focuses on metabolism-related restrictions and additive pharmacodynamic effects documented in regulatory sources.

Contraindicated Combinations Alfuzosin is formally contraindicated for co-administration with two substance categories. The first is potent CYP3A4 inhibitors, such as ketoconazole and ritonavir, as these agents significantly reduce alfuzosin clearance and increase drug exposure (AUC and Cmax up to 3.2-fold). The second is other alpha-1 receptor blockers due to the high risk of additive hypotensive effects.

Pharmacodynamic Effects Co-administration with antihypertensive medications, nitrates, and PDE5 inhibitors (e.g., sildenafil) requires caution due to an increased risk of symptomatic hypotension. Caution is also advised when combining Alfuzosin with medicines known to prolong the QTc interval. Furthermore, it is recommended that the tablets be withdrawn 24 hours before surgery involving general anaesthetics to mitigate the risk of severe blood pressure instability.

Food and Population Constraints Due to the 50% reduction in absorption when fasting, Alfuzosin must be taken with food for consistent drug levels. The use of this medicine is also contraindicated in moderate to severe hepatic impairment because elevated alfuzosin blood levels are documented in this population.

How Alfuzosin STADA Works

Alfuzosin STADA's action is defined by a precise mechanism that results in the reduction of smooth muscle tone within the lower urinary tract by interfering with sympathetic nervous system signaling.

---

Molecular Targeting of Postsynaptic alpha1-Adrenoceptors

The primary mechanism involves the drug acting as a competitive antagonist by selectively binding to alpha1-adrenoceptors, which are highly concentrated on the smooth muscle cells of the prostate and bladder neck. This binding prevents the natural neurotransmitter Norepinephrine from activating these receptors. This molecular interference acts within domains involving receptor-mediated signaling, resulting in the modulation of the system that regulates muscle tone in the area.

---

Cascade Leading to Smooth Muscle Myorelaxation

The blocking action initiates a precise cellular cascade by inhibiting the Gq-protein signaling pathway, which is normally responsible for elevating the level of intracellular calcium (Ca^2+). Since the rise in Ca^2+ is essential for muscle cells to contract and maintain tension, the inhibition of this key molecular step results in the myorelaxation (loss of tone) of the smooth muscle tissue. This mechanism is relevant in systems where alpha1-adrenoceptor-mediated pathways are the primary factor in muscle tone regulation.

---

Physiological Consequence: Decrease in Outflow Resistance

The overall physiological consequence of this targeted smooth muscle relaxation is a decrease in the physical resistance that the prostate and bladder neck tissues exert on the urethra. This action results in the reduction of the dynamic component of lower urinary tract resistance—the smooth muscle tension—and consequently decreases intra-urethral pressure. This action leads to specific physiological adjustments that define the drug's effect profile.

Alfuzosin STADA is a medicine administered orally as a 10 mg prolonged-release tablet and is intended for a once-daily regimen. The foundational principle of its use is the requirement for food-dependent intake. Patients take the tablet immediately after a meal, and critically, with the same meal each day to maintain consistent exposure to the medicine.

The administration protocol for the prolonged-release formulation places a strong emphasis on maintaining the integrity of the tablet. To ensure the proper gradual release of the active substance, the tablet must be swallowed whole with sufficient fluid and must not be chewed, crushed, or divided under any circumstances. If a dose is missed, the protocol is to skip the missed dose and continue with the next scheduled dose at the usual time, without taking a double quantity.

For most adult use, including in older adults (over 65 years), the standard 10 mg once-daily dose is maintained, and routine dose adjustment is generally not required. Usage is, however, restricted in certain patient populations. For instance, the prolonged-release tablet is contraindicated in moderate or severe hepatic impairment and not recommended for use in cases of severe renal impairment (CrCl < 30 mL/min). While the primary context is long-term management, a short, limited course of 3 to 4 days is utilized for certain acute urinary episodes. The medicine is not indicated for use in the pediatric population.

Alfuzosin STADA: Recent Clinical Evidence

Summary of Core Findings

Research has explored the use of alfuzosin, the active substance in Alfuzosin STADA, in the management of symptoms associated with benign prostatic hyperplasia (BPH). Studies primarily focus on evaluating whether alfuzosin is associated with changes in lower urinary tract symptoms (LUTS).

Clinical trials have examined the association between alfuzosin and changes in urinary flow and storage symptoms. Findings were observed across different populations and durations of use, supporting its role in symptom management. No definitive causal links or guaranteed outcomes are established across all primary outcome measures examined.

---

Study Parameters and Design

Research has evaluated the effects of alfuzosin on parameters such as maximal urinary flow rate (Q max) and residual urine volume (PVR). The mechanism of action involves the selective blocking of alpha1-adrenoceptors in the prostate, bladder base, and prostatic capsule, which is believed to lead to muscle relaxation in these areas.

Alfuzosin has been studied across various formulations, including extended-release (ER) versions. The primary endpoints in these studies focused on measuring objective improvements in urinary flow and subjective improvements in patient-reported symptom scores.

---

Key Clinical Studies

Symptom Score Evaluation

Multiple randomized, controlled trials have evaluated alfuzosin's effect on validated symptom scores, such as the International Prostate Symptom Score (IPSS). These studies have compared the treatment group to placebo groups over periods typically ranging from 3 to 12 months. Research has documented differences in median IPSS scores between the treatment and control groups.

Safety and Tolerability Profiles

Clinical trials assessed the safety and tolerability of alfuzosin across different adult patient cohorts. The most common adverse events observed in these studies generally relate to blood pressure effects. Researchers continuously evaluate the treatment in diverse cohorts to better understand its profile within the studied populations.

Key Studies & References

1. Alfuzosin STADA 10 mg prolonged release tablets - Patient Information Leaflet and Summary of Product Characteristics (SPC)

Common questions about Alfuzosin STADA (FAQ)

Q: Why can Alfuzosin STADA cause dizziness or lightheadedness, especially when first starting?

Regulatory documents state that this medicine commonly causes dizziness and lightheadedness. This is related to the risk of postural hypotension, which is a drop in blood pressure that can occur when standing up from a sitting or lying position. This risk is typically highest within a few hours of the first dose.

Q: Is it normal to feel tired or fatigued when taking Alfuzosin STADA?

Official product information indicates that asthenia, or a feeling of unusual tiredness, is listed as a common adverse reaction observed in clinical trials. This means that feeling tired or fatigued is an expected and frequently reported effect of the medicine.

Q: Is there a risk of interaction between Alfuzosin STADA and Erectile Dysfunction (ED) medications?

Caution is noted in regulatory information regarding the co-administration of this medicine with PDE5 inhibitors, the class of drugs used for Erectile Dysfunction. Taking them together may increase the risk of experiencing symptomatic hypotension, which is a drop in blood pressure that causes symptoms like dizziness or fainting.

Q: Should I inform my eye doctor about Alfuzosin STADA if I am scheduled for cataract surgery?

Regulatory information advises informing your eye surgeon if you are taking or have previously taken this medicine. This is because alpha-blockers like Alfuzosin STADA are associated with a serious condition called Intraoperative Floppy Iris Syndrome (IFIS) that has been reported during cataract or glaucoma surgery.

Q: What are the signs of a potential overdose of Alfuzosin STADA?

Overdose of alfuzosin may primarily lead to significant low blood pressure (hypotension). Other associated symptoms may include severe dizziness or fainting. Concerns about an overdose require immediate contact with emergency services or a poison control center.

Q: Can BPH symptoms return or worsen if Alfuzosin STADA is discontinued?

This medicine is used to manage the symptoms of an enlarged prostate (BPH) but does not provide a cure. Official guidance advises patients to consult their healthcare professional before stopping the medication. Since the drug manages symptoms, discontinuation may be associated with the return of BPH symptoms.

Q: What is the average time it takes for Alfuzosin STADA to reach its full therapeutic effect?

Clinical studies have shown that the full therapeutic effects of this medicine are typically evaluated over periods of 3 to 12 months of continued use. Relief of urinary symptoms is expected to be maintained throughout the 24-hour period when taken consistently.

Q: Does Alfuzosin STADA actually shrink the prostate gland?

No, the official mechanism of action is to relax the smooth muscles in the prostate and bladder neck. This muscle relaxation helps reduce resistance and improves the flow of urine. This action does not work by shrinking the actual size of the prostate gland.

Q: How long does it typically take to start noticing a difference in symptoms after beginning Alfuzosin STADA?

While the drug's action begins with the first dose, the time it takes to notice a clear improvement in urinary symptoms can vary between individuals. The full extent of the therapeutic benefits is typically assessed over several weeks or months of consistent use.

Q: Are there any major food or drink restrictions while taking Alfuzosin STADA?

Specific food interactions exist, particularly with grapefruit and grapefruit juice. These substances are known CYP3A4 inhibitors and are generally advised to be avoided as they may increase the concentration of the medicine in the body, raising the risk of low blood pressure (hypotension).

Q: Is it okay to have grapefruit juice while on Alfuzosin STADA?

Grapefruit and grapefruit juice are generally advised to be avoided while taking this medicine. They are potent inhibitors of the CYP3A4 enzyme, which can elevate the concentration of the drug in the bloodstream and increase the risk of low blood pressure.

Q: Can Alfuzosin STADA interact with common over-the-counter medications like cold remedies or antacids?

Official regulatory information focuses primarily on interactions with antihypertensive drugs and strong enzyme inhibitors. You should be aware that some specific ingredients in common OTC medicines, such as cimetidine (an H2-blocker), have been noted in drug information to potentially interact with alfuzosin.

Q: Can Alfuzosin STADA affect a man's sexual function or cause changes in ejaculation?

Ejaculation disorders have been reported as an uncommon side effect in post-marketing experience with this drug. Additionally, the official label warns of a very rare but serious risk associated with this class of medicine: priapism, which is a persistent, painful erection.

Q: What is Intraoperative Floppy Iris Syndrome (IFIS), and how is it related to Alfuzosin STADA and eye surgery?

IFIS is a serious eye condition characterized by a flaccid and billowing iris, pupil constriction, and potential iris prolapse during cataract surgery. This condition has been reported in patients taking or having previously taken alpha-1 blockers like alfuzosin, which is why communication with the surgeon is necessary.

Q: What should I watch for when first starting Alfuzosin STADA in case of an allergic reaction?

The medicine is contraindicated for individuals with known hypersensitivity (allergy) to alfuzosin. Signs of a serious allergic reaction to watch for include hives, rash, swelling of the face, throat, or tongue, and difficulty breathing or swallowing. A serious allergic reaction would require immediate contact with emergency services or a healthcare professional.

Q: What should a patient do if they experience a persistent headache after starting Alfuzosin STADA?

Headache is listed in official documentation as a common side effect of this medication. If a headache is experienced, particularly if it is severe, persistent, or does not go away, consultation with a healthcare professional is generally advised.

Q: What is the risk of low blood pressure (hypotension) with Alfuzosin STADA?

Postural hypotension (a drop in blood pressure upon standing) is listed as a common adverse reaction in official product information. This risk increases significantly if the medicine is taken alongside other medications that lower blood pressure, such as antihypertensives or nitrates.

Q: Can Alfuzosin STADA interact with herbal supplements?

Alfuzosin is metabolized by the CYP3A4 enzyme. Therefore, any herbal supplement that is a potent inhibitor of this enzyme could increase the levels of the drug in your system. Patients are generally advised by regulatory guidance to inform their doctor about all supplements they are taking.

Q: Why do some people feel more dizzy or lightheaded in hot weather or after exercise when taking Alfuzosin STADA?

This effect is related to the known risk of postural hypotension. Situations that can cause your blood pressure to drop naturally, such as heavy exercise, prolonged standing, dehydration, or exposure to excessive heat, can intensify the lightheadedness caused by the medicine.

Q: Is Alfuzosin STADA safe to take with common anti-inflammatory pain relievers?

The official product information does not list all common anti-inflammatory pain relievers (NSAIDs) as contraindications. However, some of these medications can affect blood pressure and kidney function. Caution is advised for patients with underlying risk factors such as heart or kidney impairment.

Q: Does Alfuzosin STADA work similarly to other alpha-1 blockers like Doxazosin or Terazosin?

Yes, Alfuzosin STADA belongs to the same class of medicines known as alpha-1 receptor blockers. Because they work similarly, official regulatory information formally contraindicates the use of this medicine with any other alpha-1 receptor blocking agent due to the serious risk of additive blood pressure lowering effects.

Alfuzosin prolonged-release tablets must be stored according to regulatory requirements to preserve the medication's stability and integrity.

• Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. This medicine must be protected from freezing.
• Handling and Protection: Keep the tablets in the original container, tightly closed, and away from excessive moisture and heat.
• Child Safety: It is a mandatory requirement to keep this medicine out of the sight and reach of children.
• Disposal: Unused or expired medication must not be disposed of in wastewater or general household trash. Disposal must be carried out in accordance with local regulations or official drug take-back programs.